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Abstract 
Background: The objective of this study was to review changes in the prevalence of opioid use disorder in preg-
nancy, and to describe the prenatal care and neonatal outcomes following the implementation of buprenorphine 
treatment at a large US obstetrical clinic during the on-going opioid epidemic.
Methods: We conducted a retrospective cohort study of 310 women (332 pregnancies) with opioid use disorders 
and their neonates delivered between June 2006 and December 2010 at an obstetrical clinic in the US. Trends in 
patient volume, characteristics and outcomes by calendar year were assessed using the Cochran–Armitage test and 
linear regression.
Results: There was an almost two-fold increase in the volume of pregnant women treated annually from 2006 
through 2010. Most women were treated with methadone (74%), with buprenorphine becoming more common 
over calendar time: 3.0% in 2006 to 41% in 2010. The mean dose of buprenorphine at delivery was: 11.4 mg in 2007, 
14.1 mg in 2008, 14.1 mg in 2009, and 16.8 mg in 2010; an average increase of 2.1 mg year. There were no differences 
in mean methadone dose over time. From 2006 to 2010 there were increases in the prevalence of prescribed con-
comitant psychotropic medications and vaginal deliveries, and in the proportion of neonates treated pharmacologi-
cally for neonatal abstinence syndrome (NAS). NAS pharmacologic management also varied by calendar year with 
more use of neonatal morphine and clonidine in later years.
Conclusions: The number of mother–infant pairs increased significantly from 2006 to 2010 and the clinical char-
acteristics of these patients changed over time. Our experience reflects the rising increase in opioid use disorders in 
pregnancy and NAS, mandating the need for expansion of comprehensive prenatal care options for these women 
and their children.
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Background
Opioid use disorders affect a rising number of women 
of childbearing age [1]. From 2000 to 2009, opioid use 
among US pregnant women increased from 1.19 per 1000 
hospital births to 5.63 per 1000 hospital births per year 
[2]. National attention has been given to the rising inci-
dence of Neonatal Abstinence Syndrome (NAS) in the 
US, which is associated with the rise in opioid use dis-
orders in pregnancy. NAS is a constellation of signs and 
symptoms of withdrawal from in utero exposure to opi-
oids and other substances. NAS incidence increased five-
fold between 2000 and 2012, currently accounting for 3% 
of admissions to neonatal intensive care units (NICUs) in 
the US [3]. Reducing the incidence of NAS begins with 
prevention of opioid use disorders during the childbear-
ing years. Improving maternal and neonatal outcomes for 
these dyads requires expanded access to opioid treatment 
programs for pregnant women. Recognizing the barriers 
to care such as socioeconomic challenges, potential legal 
consequences, intimate partner violence and psychiatric 
comorbidities is paramount to providing effective and 
accessible treatment options for this population [4].
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The introduction of office based prescribing of 
buprenorphine has increased access to opioid use dis-
order treatment in the US and allows for integration of 
opioid agonist treatment in prenatal clinic settings [5]. 
Historically, opioid agonist treatment with methadone 
was the gold standard for managing opioid use disor-
ders in pregnant women. Based on geographic location, 
however, many women do not have access to a metha-
done treatment facility in the US [6, 7]. In addition, most 
obstetricians have limited training in addiction medicine 
or substance use disorder screening methods and are 
unable to provide comprehensive care for these patients 
[8, 9]. Even in areas where such infrastructure exists, 
many women are resistant to starting methadone cit-
ing the stigma of methadone treatment and the restric-
tions of daily dosing as the major barriers [7]. The Project 
Recovery-Empowerment-Social Services-Prenatal Care-
Education-Community-Treatment (RESPECT), Sub-
stance Use Disorder Treatment in Pregnancy Clinic, a 
multidisciplinary program based at an urban, academic 
center was developed in response to these issues. The 
objectives of this study are to describe changes at our 
center in the prevalence of opioid use disorder in preg-
nancy, the delivery of prenatal care, and neonatal out-




We conducted a retrospective cohort study of pregnant 
women with opioid use disorder and their neonates 
delivered at Boston Medical Center from June 2006—
when buprenorphine treatment began in our Project 
RESPECT clinic—through December 2010. Project 
RESPECT is a multidisciplinary treatment team at Bos-
ton Medical Center consisting of three buprenorphine 
waivered obstetric providers, a psychiatrist, an addiction 
psychiatry nurse practitioner, and a licensed independent 
clinical social worker. Boston Medical Center is an urban 
safety net hospital with a labor and delivery unit, high-
risk maternal fetal medicine in-patient service, level three 
NICU and a pediatric in-patient ward for infants with 
NAS. Project RESPECT operates in conjunction with 
local and regional methadone clinics, counseling centers, 
and residential treatment programs for pregnant women.
Maternal criteria for opioid agonist therapy at Pro-
ject RESPECT included being 18  years of age or older, 
DSM IV diagnosis of substance dependence for opi-
oids, laboratory and/or radiographic documentation 
of pregnancy, and voluntary consent to engage in Pro-
ject RESPECT’s comprehensive treatment program. All 
Project RESPECT patients treated with opioid agonist 
treatment (methadone or buprenorphine) were followed 
by the same specialized team. The type of opioid agonist 
treatment initiated was selected considering the follow-
ing factors: patient choice, treatment history, disease 
severity and medical and psychiatric comorbidities.
Our practice protocol recommends methadone for 
women with more severe opioid use disorder, women 
with intolerance to buprenorphine, or for whom 
buprenorphine is medically contraindicated. In general, 
women for whom previous buprenorphine treatment 
was non-efficacious, who had a history within the last 
6 months of buprenorphine diversion, who were unable 
to present for weekly to bi-weekly office visits, or who 
were unwilling to engage in independent relapse preven-
tion counseling were offered methadone. All patients 
were scheduled for a prenatal care and relapse prevention 
visit every 1–3 weeks from initiation of care until deliv-
ery. Observed urine drug tests were done at every pre-
natal visit and on admission to labor and delivery. If an 
appointment was missed, patients were contacted and 
requested to come in for a urine drug test within 48 h.
Study data
Study data were obtained from electronic medical 
records and included maternal age, total number of 
prenatal visits, urine drug test results, gestational age 
at treatment initiation, methadone or buprenorphine 
dose at treatment initiation and at delivery, concomitant 
medication use, smoking during pregnancy, gestational 
age at delivery, mode of delivery, anesthesia use during 
delivery, infant birth weight, neonatal abstinence score 
using a modified Finnegan scale, amount and duration 
of NAS opioid treatment and length of neonatal hospi-
tal stay [10]. Neonatal treatment with opioid therapy 
was initiated if the neonate had three consecutive modi-
fied Finnegan scores ≥8 or two consecutive scores ≥12. 
Neonates delivered June 2006 through mid-January 2009 
had first-line treatment with diluted tincture of opium 
(DT0) of 0.4  mg morphine/mL, and neonates delivered 
mid-January 2009 through December 2010 had first-
line treatment with neonatal morphine solution. Results 
were converted to total morphine in equivalents over the 
course of the hospitalization. Morphine dosing was based 
on both severities of scores and neonatal birth weight. 
Adjunctive therapy with phenobarbital or clonidine 
was added for infants who continued to have scores >8 
despite maximum dosing of DTO or morphine. Infants 
were weaned off DTO, morphine, and/or clonidine as 
inpatients and monitored for 24–48 h prior to discharge. 
Phenobarbital was weaned in the outpatient setting. This 
study was approved by the Boston University Medical 
Center Institutional Review Board.
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Statistical methods
Trends in the treatment of mother–neonate pairs by cal-
endar year were assessed using the Cochran–Armitage 
test for categorical variables and linear regression for 
continuous variables. For the linear trend model, year 
of birth was standardized to have a mean of zero and a 
standard deviation of 1 because of the small range of val-
ues relative to the mean in the original distribution. Dif-
ferences in binary maternal and infant characteristics by 
prenatal exposure (methadone or buprenorphine) and 
calendar year were estimated using generalized linear 
models (log-link function) because the odds ratio overes-
timates the risk ratio given the high risk of our outcomes 
[11]. Linear regression was used to estimate differences 
in continuous outcomes. Women with >1 pregnancy 
were included for each pregnancy. Five women initiated 
therapy with buprenorphine and later were switched to 
methadone; these mother–neonate pairs are described, 
but were not included in our statistical models. One 
twin from each twin birth was included; analyses were 
run including and excluding the twin and results were 
unchanged. We did not account for the clustering in the 
small number of women (N = 20) who delivered infants 
from >1 pregnancy. Statistical analyses were carried out 
with SAS 9.3.
Results
A total of 316 pregnant opioid dependent women pre-
sented for care during the study period: 296 women had 
one pregnancy, 18 had two pregnancies, and two had 
three pregnancies; there were six sets of twins. Of the 338 
pregnancies, 6 resulted in intrauterine fetal demise or still 
birth and the remaining were live births. The final study 
population included 332 mother neonate pairs from 332 
pregnancies (including one twin from each of the six sets 
of twins) in 310 women.
The number of pregnant women with opioid use disor-
ders rose from 2006 through 2010. There was an almost 
two-fold increase in the number of women treated annu-
ally from 2007 through 2010. Following the emergence 
of buprenorphine as a treatment option at our clinic in 
2006, women treated with buprenorphine for opioid use 
disorder increased from 3% in 2006 to 41% in 2010. The 
delivery dose of buprenorphine increased on average by 
2.1 mg per year from 2007 to 2010 but no such trend in 
the average methadone dose at delivery was found. The 
prevalence of prescribed concomitant psychotropic 
medications increased as well as the proportion of vagi-
nal deliveries (Table  1). There was a slight decrease in 
the proportion of maternal urine drug tests positive for 
cocaine. The proportion of neonates treated pharmaco-
logically for NAS increased over time.
There were some notable differences in maternal char-
acteristics by opioid agonist treatment type (Table  2). 
Women treated with buprenorphine versus methadone 
were more likely to deliver in later calendar years, to have 
on average three more prenatal care visits, and had a 15% 
increased likelihood of vaginal delivery. Buprenorphine 
treated women had a 26% lower risk of a positive urine 
screen for any illicit drug after treatment initiation, 76% 
lower risk of a positive cocaine screen and 31% lower risk 
of a positive opioid screen compared to those treated 
with methadone.
Neonatal characteristics and NAS outcomes by calen-
dar year are provided in Table 3. Following the changes in 
prenatal opioid agonist therapy at our site, the proportion 
of infant exposed to buprenorphine increased over time. 
The proportion of infants treated pharmacologically for 
NAS also increased from 76% in 2006 to 86% in 2010. The 
length of NAS treatment appears to have decreased fol-
lowing the replacement of DTO with morphine as a first 
line NAS treatment in 2009 despite a trend towards treat-
ment starting earlier as year of birth increased. There 
was no discernable trend in the amount of morphine per 
birth weight by year of delivery. Mean gestational age at 
birth was stable over time and above 37  weeks, but the 
proportion of infants born preterm was overall high.
Discussion
We describe outcomes of pregnant women with opi-
oid use disorders and their neonates treated at our 
Project RESPECT clinic from 2006 to 2010. Over the 
study period, the percentage of women treated with 
buprenorphine increased from 3 to 41%, possibly reflect-
ing increases in patient demand, increased patient 
autonomy, and improved provider prescribing comfort. 
Buprenorphine treatment failure, defined as transition 
from buprenorphine to methadone during the preg-
nancy for non-adherence, did not show a corresponding 
increase. The increase in the average dose of buprenor-
phine prescribed over the study period may be the result 
of several factors including, an increase in provider pre-
scribing comfort over time and an increase in addiction 
disease severity in those seeking buprenorphine treat-
ment. Choosing the appropriate agonist medication for 
pregnant women with opioid use disorder is complex; 
multiple variables including patient preference, disease 
severity, psychiatric comorbidities, social supports and 
recovery resources must be considered.
There were important differences observed in the char-
acteristics of women by treatment approach. Women 
treated with buprenorphine versus methadone attended 
more prenatal care visits and had fewer positive urine 
drug tests. In addition, these women were more likely to 
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delivery vaginally, likely due to changes in operative deliv-
ery recommendations for hepatitis C positive women. 
After 2007, cesarean sections were no longer recom-
mended to decrease vertical transmission of hepatitis C. 
From 2006 to 2010, our cesarean section rate decreased 
from 45.8 to 35%, with the largest number of buprenor-
phine patients delivering in the later calendar years.
Maternal severity of opioid dependence and other fac-
tors influenced our clinical prescribing, with buprenor-
phine typically being used in more stable pregnant 
women who do not need the structure of observed daily 
dosing [12]. Potential confounding by indication can 
occur in assessing the comparative outcomes of prena-
tal BMT versus MMT because maternal characteristics 
that might influence choice of prenatal treatment with 
BMT versus MMT likely also affect neonatal outcomes 
[13, 14]. Prior studies have suggested improved NAS and 
birth outcomes in neonates exposed to buprenorphine 
compared to methadone, including decreased NAS 
severity with shorter length of hospitalization, lower risk 
of NAS pharmacologic treatment, and higher gestational 
age at birth, birth weight, body length and head circum-
ference [15–17]. Because of the potential for uncon-
trolled confounding in this and many studies published 
to date [18] we did not assess any causal relationships 
between prenatal exposure and infant outcomes. Further, 
the dynamic nature of clinical care in this patient popula-
tion, including changes in both maternal treatment and 
in NAS treatment, can introduce misclassification bias in 
any causal assessments.
We observed changes in NAS care practices in our 
institution over the calendar years, including a shift from 
DTO to neonatal morphine solution as first-line treat-
ment, and more clonidine use for adjunctive second-line 
treatment. These observed changes fit with the updated 
recommendations for NAS management over the past 
Table 1 Maternal characteristics by calendar year for 332 pregnancies
Missing data: Initial daily dose of opioid agonist therapy, one women treated with buprenorphine in 2008, one women treated with buprenorphine in 2009, one 
women treated with buprenorphine in 2010, one women treated with methadone in 2006, two women treated with methadone in 2007, one woman treated with 
methadone in 2009; Gestational age at first prenatal visit, two women in 2006, six women in 2007, three women in 2008, five women in 2009, two women in 2010. 
Smoking, 6 women in 2006, 10 women in 2007, 16 women in 2008, 15 women in 2009, 18 women in 2010; Hepatitis C, 10 women in 2006, 14 women in 2007, 15 
women in 2008, 17 women in 2009, 18 women in 2010. Anesthesia, 5 women in 2006, 2 women in 2007, 3 women in 2008, 3 women in 2009, 3 women in 2010
Mean ± standard deviation or number of pregnancies and percent











Maternal age (years) 27.4 (6.0) 28.8 (5.8) 28.6 (4.7) 27.2 (4.8) 27.3 (4.7)
Gestational age at presentation for care (weeks) 18.6 (9.1) 17.0 (8.0) 18.7 (9.7) 15.3 (7.7) 16.4 (9.9)
Number of prenatal care visits 8.9 (4.9) 9.6 (4.6) 9.6 (5.0) 9.4 (4.4) 9.3 (4.3)
Initial daily dose of methadone (mg) 70.9 (35.1) 66.1 (36.4) 74.2 (49.2) 66.6 (34.0) 64.9 (29.4)
Daily dose of methadone at delivery (mg) 88.5 (36.8) 83.8 (40.4) 94.4 (52.7) 91.0 (40.8) 88.0 (35.1)
Initial daily dose of buprenorphine (mg) – 11.6 (7.0) 10.1 (4.0) 13.2 (6.5) 12.2 (7.2)
Daily dose of buprenorphine at delivery (mg) – 11.4 (8.4) 14.1 (6.4) 14.1 (6.1) 16.8 (8.4)
Prescribed psychiatric medications
 SSRIs 3 (9.1) 4 (7.6) 14 (20.3) 13 (15.5) 20 (21.5)
 Benzodiazepines 5 (15.2) 10 (18.9) 15 (21.7) 15 (17.9) 20 (21.5)
 Antipsychotics 0 (0) 4 (7.6) 4 (5.8) 4 (4.8) 7 (7.5)
 Other 2 (6.1) 1 (1.9) 5 (7.3) 8 (9.5) 10 (10.8)
Smoked cigarettes 25 36 42 59 59
Hepatitis C infected 19 27 38 48 48
≥1 urine screen 31 (93.9) 50 (94.3) 69 (98.6) 79 (94.0) 88 (94.6)
≥1 positive urine screen 15 (48.4) 22 (44.0) 38 (55.9) 41 (51.9) 43 (48.9)
Urine screen positive fora
 Cocaine 10 (32.3) 11 (22.0) 16 (23.5) 18 (22.8) 16 (18.2)
 Opioids 11 (35.5) 14 (28.0) 26 (38.2) 32 (40.5) 44 (38.6)
 Benzodiazepines 1 (3.2) 4 (8.0) 9 (13.2) 8 (10.1) 3 (3.4)
 Amphetamines 1 (3.2) 1 (2.0) 3 (4.4) 2 (2.5) 3 (3.4)
Vaginal delivery 16 (48.5) 27 (50.9) 38 (55.1) 53 (63.1) 62 (66.7)
Cesarean section 17 (55.5) 26 (49.1) 31 (44.9) 31 (36.9) 31 (33.3)
Anesthesia during delivery 25 (75.7) 48 (90.5) 60 (86.9) 76 (90.4) 81 (87.0)
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Table 2 Maternal characteristics by prenatal opioid agonist treatment for 332 pregnancies
Characteristic Mean and standard deviation or number 
and proportion
Mean difference or risk ratio and 95% CI (adjusted for year 
of birth)




Maternal age (years) 28.1 ± 5.1 27.7 ± 5.1 27.2 ± 3.3 0.76 (−0.55, 2.07)
Year of deliverya
 2009–2010 60 (73.2) 114 (46.5) 3 (60.0) 1.57 (1.30, 1.90)
 2006–2008 22 (26.8) 131 (53.5) 2 (40.0) 1.0
Number of fetuses
 Singleton 80 (97.6) 241 (98.4) 5 (100) –
 Twin 2 (2.4) 4 (1.6) 0 (0)
 Prenatal care 82 (100) 241 (0.99) 5 (100) –
 Gestational age at presenta-
tion for care (weeks)
16.4 ± 8.9 17.2 ± 8.9 11.8 ± 8.6 −0.16 (−2.46, 2.13)
 Number of prenatal care visits 11.5 ± 4.7 8.7 ± 4.3 11.6 ± 2.2 3.06 (1.92, 4.20)
 Initial daily dose of opioid 
agonist therapy (mg)
12.0 ± 6.5 68.3 ± 37.4 12.0 ± 4.0 –
Stopped agonist therapy during pregnancy
 Yes 2 (2.4) 0 (0) 0 (0) –
 No 80 (97.6) 245 (100) 5 (100)
Daily dose of opioid agonist 
therapy at delivery (mg)
15.1 ± 7.5 89.3 ± 41.7 77.0 ± 28.9 –
Smoked cigarettes 54 (65.9) 164 (66.9) 4 (80.0) –
Hepatitis C infected 32 (39.0) 134 (54.7) 4 (80.0) –
Prescribed SSRIs 14 (17.1) 38 (15.5) 2 (40.0) 1.01 (0.57, 1.79)
1.0
Prescribed benzodiazepines 14 (17.1) 51 (20.8) 0 (0) 0.81 (0.47, 1.39)
1.0
Prescribed antipsychotics 1 (1.2) 18 (7.4) 0 (0) 0.15 (0.02, 1.12)
1.0
Other prescribed psychiatric 
medications
9 (11.0) 15 (6.1) 2 (40.0) 1.60 (0.72, 3.60)
1.0
Urine screen
 ≥1 78 (95.1) 233 (95.1) 5 (100) 1.02 (0.95, 1.09)
 None 4 (4.9) 12 (4.9) 0 (0) 1.0
Positive urine screen
 ≥1 31 (39.7) 123 (52.8) 5 (100) 0.74 (0.55, 1.01)
 None 47 (60.3) 220 (47.2) 0 (0) 1.0
Cocaine urine screen
 Positive 5 (6.4) 63 (27.0) 3 (60.0) 0.24 (0.10, 0.57)
 Negative 73 (93.6) 170 (73.0) 2 (40.0) 1.0
Non-prescribed opioid urine screen
 Positive 22 (28.2) 90 (38.6) 5 (100) 0.69 (0.46, 1.02)
 Negative 56 (71.8) 143 (61.4) 0 (0) 1.0
Non-prescribed benzodiazepines urine screen
 Positive 7 (9.0) 18 (7.7) 0 (0) 1.27 (0.54, 2.98)
 Negative 71 (91.0) 215 (92.3) 5 (100) 1.0
Non-prescribed amphetamine urine screen
 Positive 3 (3.9) 7 (3.0) 0 (0) 1.34 (0.34, 5.31)
 Negative 75 (96.1) 226 (97.0) 5 (100) 1.0
Mode of delivery
 Vaginal 55 (67.1) 138 (56.3) 3 (60.0) 1.15 (0.95, 1.39)
 Cesarean section 27 (32.9) 107 (43.7) 2 (40.0) 1.0
Page 6 of 8Saia et al. Addict Sci Clin Pract  (2017) 12:5 
decade. Morphine and methadone are recommended by 
the American Academy of Pediatrics (AAP) as preferred 
agents over DTO [19, 20]. While the majority of institu-
tions in the US use morphine, a recent single-center rand-
omized control trial found that methadone was associated 
with shorter hospitalizations in comparison with mor-
phine [21]. In addition, some institutions have started 
to transition infants home on methadone to complete 
weaning [22, 23]. Recent national trends in adjunctive 
medications for NAS favor clonidine as an acceptable 
option over phenobarbital [24, 25]. There is also a trend 
towards more emphasis on breastfeeding, rooming-in, 
and other non-pharmacologic care interventions to best 
manage NAS [18, 26]. Lastly, though the Finnegan scale 
is the current gold standard for NAS assessments, newer 
scales are under development [26]. Significant variability 
in NAS care remains and there is a need for more high 
quality clinical trials to best guide management.
Missing data: Initial daily dose of opioid agonist therapy, three women treated with buprenorphine, six women treated with methadone; Gestational age at 
first prenatal visit, one woman treated with methadone. Number of prenatal care visits, two women treated with methadone; Smoking, 12 women treated 
with buprenorphine, 52 women treated with methadone, 1 woman treated with methadone and buprenorphine; Hepatitis C infection, 11 women treated with 
buprenorphine, 62 women treated with methadone, 1 woman treated with methadone and buprenorphine; Anesthesia, one women treated with buprenorphine, and 
15 women treated with methadone
a Unadjusted result
Table 2 continued
Characteristic Mean and standard deviation or number 
and proportion
Mean difference or risk ratio and 95% CI (adjusted for year 
of birth)





 Yes 76 (93.8) 209 (90.9) 5 (100) 1.03 (0.96, 1.11)
 No 5 (6.2) 21 (9.1) 0 (0) 1.0
Table 3 Neonatal characteristics by year of birth
Missing data: Birth weight, one neonate; Length of stay, one neonate; Total mg of morphine per kg of birth weight: one neonate; Peak Finnegan Score, twelve 
neonates
NAS neonatal abstinence syndrome, DTO diluted tincture of opium











Prenatal opioid agonist therapy exposure
 Methadone 32 (97.0) 48 (90.6) 51 (79.3) 62 (73.8) 52 (55.9)
 Buprenorphine 1 (3.3) 5 (9.4) 16 (23.2) 22 (26.2) 38 (40.9)
 Methadone and buprenorphine 0 (0) 0 (0) 2 (2.9) 0 (0) 3 (3.2)
Length of hospitalization (days) 23.2 ± 10.3 24.2 ± 12.7 24.1 ± 12.9 21.9 ± 11.1 20.8 ± 10.9
Pharmacologically treated for NAS 25 (75.8) 43 (81.1) 62 (89.9) 72 (85.7) 80 (86.0)
Age at NAS treatment Initiation (days) 2.5 ± 2.1 2.4 ± 1.9 2.9 ± 3.1 2.0 ± 1.7 1.9 ± 1.4
First-line NAS treatment
 Morphine 0 (0) 0 (0) 1 (1.6) 67 (93.1) 80 (100.0)
 DTO 25 (100) 43 (100) 61 (98.4) 5 (6.9) 0 (0)
Total morphine used to treat NAS, mg per kg birth weighta 6.0 ± 3.7 6.7 ± 6.2 3.6 ± 3.5 8.9 ± 8.4 6.4 ± 5.4
Additional NAS treatment with
  Phenobarbital
9 (36.0) 9 (20.9) 10 (16.1) 23 (31.9) 18 (22.5)
 Clonidine 0 (0) 0 (0) 0 (0) 2 (2.8) 8 (10.0)
Length of NAS treatment (days) 20.6 ± 9.6 20.6 ± 10.2 19.5 ± 10.1 19.2 ± 9.5 17.5 ± 7.8
Peak Finnegan score among neonates treated for NAS 13.9 ± 2.8 13.3 ± 3.5 11.9 ± 2.6 12.9 ± 3.0 11.9 ± 2.5
Gestational age at birth (weeks) 37.9 ± 1.8 38.7 ± 2.2 38.0 ± 2.5 38.2 ± 2.5 38.7 ± 2.3
Preterm birth (<37 weeks) 7 (21.2) 6 (11.3) 17 (24.6) 16 (19.1) 12 (12.9)
Birth weight (g) 2895.8 ± 373.1 2786.6 ± 728.0 2807.9 ± 599.6 2898.5 ± 652.3 2974.2 ± 580.2
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Strengths of our study include being conducted at a sin-
gle large clinic that is a leader in addiction medicine with 
standardized approaches for treating prenatal opioid use 
disorders and for assessing and treating NAS, and the 
largest sample size of opioid dependent mother–neonate 
pairs studied to date. Limitations of our study include the 
potential for error in chart abstraction and limited vari-
ables available clinically, especially potential confounders. 
Our institutional NAS clinical guidelines changed mid-
way through the study period to use of neonatal morphine 
solution versus DTO as first-line therapy. Although DTO 
was converted to morphine equivalent dose, some differ-
ences in the pharmacology of these treatments may exist.
Conclusions
The choice of opioid agonist treatment remains a com-
plex issue, with the overriding goal of maintaining 
maternal stability throughout the pregnancy and the 
post-partum period to improve both maternal and neo-
natal outcomes. Future research is needed to evaluate 
whether maternal addiction severity and choice of opioid 
agonist treatment affect neonatal outcomes and maternal 
long-term recovery. Accessible prenatal care combined 
with opioid use disorder treatment for pregnant women 
in the US must be adopted to address the needs of this 
underserved and growing population. Boston Medical 
Center’s obstetric care and addiction medicine treatment 
clinic, Project RESPECT, demonstrates the feasibility of 
such a model in a large urban center. Reducing health 
care costs and improving the care for opioid-exposed 
newborns cannot be accomplished without parallel 
development and implementation of comprehensive care 
for opioid dependent pregnant women.
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